The polycystic ovary syndrome: A position statement from the European Society of Endocrinology

European Journal of Endocrinology

Volumn 171, Issue 4, 2014, Pages P1-P29

  Conway, Gerard ^a   Dewailly, Didier ^b   Diamanti Kandarakis, Evanthia ^c   Escobar Morreale, Héctor F ^d   Franks, Stephen ^e   Gambineri, Alessandra ^f   Kelestimur, Fahrettin ^g   Macut, Djuro ^h   Micic, Dragan ^h   Pasquali, Renato ^f   Pfeifer, Marija ⁱ   Pignatelli, Duarte ^j   Pugeat, Michel ^k   Yildiz, Bulent O ^l  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY OF ALCALÁ   (Spain)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g ERCIYES UNIVERSITY   (Turkey)

^h UNIVERSITY OF BELGRADE   (Serbia)

ⁱ UNIVERSITY OF LJUBLJANA   (Slovenia)

^j HOSPITAL DE SÃO JOÃO   (Portugal)

^k UNIVERSITÉ LYON 1   (France)

^l HACETTEPE UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANDROSTENEDIONE; ANTIBIOTIC AGENT; CYPROTERONE ACETATE; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; EXENDIN 4; FINASTERIDE; FLUTAMIDE; FOLLITROPIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; METFORMIN; MUELLERIAN INHIBITING FACTOR; PIOGLITAZONE; PRASTERONE SULFATE; PROGESTERONE; RETINOIC ACID DERIVATIVE; ROSIGLITAZONE; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; TESTOSTERONE; VITAMIN D; ANDROGEN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE; SEX HORMONE;

ABDOMINAL OBESITY; ACNE; ADRENARCHE; ALOPECIA; ANDROGEN BLOOD LEVEL; ANXIETY DISORDER; ARTERY DISEASE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BARIATRIC SURGERY; BODY FAT DISTRIBUTION; BODY WEIGHT DISORDER; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTRACEPTION; CORONARY ARTERY CALCIFICATION; DEPRESSION; DISEASE ASSOCIATION; DRUG MEGADOSE; EATING DISORDER; EDEMA; ELECTROLYSIS; ENDOTHELIAL DYSFUNCTION; ESTHETIC SURGERY; ESTROGEN BLOOD LEVEL; EXPOSURE; FOLLITROPIN BLOOD LEVEL; HEADACHE; HIRSUTISM; HORMONE DETERMINATION; HUMAN; HYPERANDROGENISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INTENSE PULSED LIGHT THERAPY; INTRAUTERINE GROWTH RETARDATION; LIBIDO DISORDER; LIFE EVENT; LIFESTYLE MODIFICATION; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; LOW BIRTH WEIGHT; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; METABOLIC DISORDER; MOOD DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITION; OBESITY; OLIGOMENORRHEA; OVARY FOLLICLE; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; OXIDATIVE STRESS; PREMATURE ADRENARCHE; PROTEOMICS; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; SLEEP DISORDERED BREATHING; SOCIAL PHOBIA; SUICIDE ATTEMPT; TANDEM MASS SPECTROMETRY; TESTOSTERONE BLOOD LEVEL; TRANSVAGINAL ECHOGRAPHY; VENOUS THROMBOEMBOLISM; VITAMIN D DEFICIENCY; WEIGHT REDUCTION; BLOOD; BODY COMPOSITION; CONCEPT FORMATION; ECHOGRAPHY; FEMALE; FEMALE INFERTILITY; GLUCOSE INTOLERANCE; LIPID PEROXIDATION; METABOLISM; OVARY; PATHOLOGY; PHENOTYPE; PRACTICE GUIDELINE; PSYCHOLOGICAL ASPECT; REVIEW; RISK REDUCTION;

POLYCYSTIC OVARY SYNDROME; ANDROGENS; BARIATRIC SURGERY; BIOLOGICAL MARKERS; BODY COMPOSITION; CARDIOVASCULAR DISEASES; CONCEPT FORMATION; FEMALE; GLUCOSE; GLUCOSE INTOLERANCE; GONADAL STEROID HORMONES; HUMANS; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; INSULIN RESISTANCE; LIPID PEROXIDATION; OBESITY; OVARY; PHENOTYPE; QUALITY OF LIFE; RISK REDUCTION BEHAVIOR; TESTOSTERONE;

EID: 84907225391     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0253     Document Type: Article

References (285)

1. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R & Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2013 98 4565-4592. (doi:10.1210/jc.2013-2350)
2. Azziz R, Marin C, Hoq L, Badamgarav E & Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. Journal of Clinical Endocrinology and Metabolism 2005 90 4650-4658. (doi:10.1210/jc.2005-0628)
3. Stein IF & Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. American Journal of Obstetrics and Gynecology 1935 29 181.
4. Zawadzki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rationale approach. In Polycystic Ovary Syndrome, pp 377-384. Eds A Dunaif, JR Givens, FP Haseltine & GR Merriam, Boston: Blackwell Scientific Publications, 1992.
5. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004 19 41-47. (doi:10.1093/humrep/deh098)
6. Cussons AJ, Stuckey BG, Walsh JP, Burke V & Norman RJ. Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clinical Endocrinology 2005 62 289-295. (doi:10.1111/j.1365-2265.2004.02208.x)
7. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and Sterility 2009 91 456-488. (doi:10.1016/j.fertnstert.2008.06.035)
8. Diamanti-Kandarakis E & Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews 2012 33 981-1030. (doi:10.1210/er.2011-1034)
9. Moran LJ, Misso ML, Wild RA & Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2010 16 347-363. (doi:10.1093/humupd/dmq001)
10. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility 2012 97 28-38. (doi:10.1016/j.fertnstert.2011.09.024)
11. Ehrmann D. Polycystic ovary syndrome. New England Journal of Medicine 2005 352 1223-1236. (doi:10.1056/NEJMra041536)
12. Final Report National Institute of Health. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome December 3-5, 2012 Executive summary at http://prevention.nih.gov/workshops/2012/pcos/resourc-es.aspx.
13. Dunaif A & Fauser BC. Renaming PCOS - a two state solution. Journal of Clinical Endocrinology and Metabolism 2013 98 4325-4328. (doi:10.1210/jc.2013-2040)
14. Xita N & Tsatsoulis A. Review: Fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. Journal of Clinical Endocrinology and Metabolism 2006 91 1660-1666. (doi:10.1210/jc.2005-2757)
15. Dumesic DA & Richards JS. Ontogeny of the ovary in polycystic ovary syndrome. Fertility and Sterility 2013 100 23-38. (doi:10.1016/j.fertnstert.2013.02.011)
16. Dumesic DA, Abbott DH & Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Reviews in Endocrine & Metabolic Disorders 2007 8 127-141. (doi:10.1007/s11154-007-9046-0)
17. Franks S & Berga SL. Does PCOS have developmental origins? Fertility and Sterility 2012 97 2-6. (doi:10.1016/j.fertnstert.2011.11.029)
18. Welt CK & Carmina E. Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. Journal of Clinical Endocrinology and Metabolism 2013 98 4629-4638. (doi:10.1210/jc.2013-2375)
19. de Zegher F, Lopez-Bermejo A & Ibáñez L. Adipose tissue expandability and the early origins of PCOS. Trends in Endocrinology and Metabolism 2009 20 418-423. (doi:10.1016/j.tem.2009.06.003)
20. Ibáñez L, de Zegher F & Potau N. Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. Journal of Endocrinological Investigation 1998 21 558-566. (doi:10.1007/BF03350781)
21. Meas T, Chevenne D, Thibaud E, Léger J, Cabrol S, Czernichow P & Lévy-Marchal C. Endocrine consequences of premature pubarche in post-pubertal Caucasian girls. Clinical Endocrinology 2002 57 101-106. (doi:10.1046/j.1365-2265.2002.01579.x)
22. Markopoulos MC, Valsamakis G, Kouskouni E, Boutsiadis A, Papassotiriou I, Creatsas G & Mastorakos G. Study of carbohydrate metabolism indices and adipocytokine profile and their relationship with androgens in polycystic ovary syndrome after menopause. European Journal of Endocrinology 2012 168 83-90. (doi:10.1530/EJE-12-0550)
23. Schmidt J, Dahlgren E, Brännström M & Landin-Wilhelmsen K. Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome - a long-term follow-up study. Clinical Endocrinology 2012 77 207-214. (doi:10.1111/j.1365-2265.2012.04378.x)
24. Schmidt J, Landin-Wilhelmsen K, Brännström M & Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. Journal of Clinical Endocrinology and Metabolism 2011 96 3794-3803. (doi:10.1210/jc.2011-1677)
25. Markopoulos MC, Rizos D, Valsamakis G, Deligeoroglou E, Grigoriou O, Chrousos GP, Creatsas G & Mastorakos G. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. Journal of Clinical Endocrinology and Metabolism 2011 96 623-631. (doi:10.1210/jc.2010-0130)
26. Polotsky AJ, Allshouse AA, Crawford SL, Harlow SD, Khalil N, Kazlauskaite R, Santoro N & Legro RS. Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition. Journal of Clinical Endocrinology and Metabolism 2014 99 2120-2127. (doi:1210/jc.2013-4170)
27. Polotsky AJ, Allshouse A, Crawford SL, Harlow SD, Khalil N, Santoro N & Legro RS. Relative contributions of oligomenorrhea and hyperandrogenemia to the risk of metabolic syndrome in midlife women. Journal of Clinical Endocrinology and Metabolism 2012 97 E868-E877. (doi:10.1210/jc.2011-3357)
28. Panidis D, Macut D, Tziomalos K, Papadakis E, Mikhailidis K, Kandaraki EA, Tsourdi EA, Tantanasis T, Mavromatidis G & Katsikis I. Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clinical Endocrinology 2013 78 586-592. (doi:10.1111/cen.12008)
29. Gambineri A, Repaci A, Patton L, Grassi I, Pocognoli P, Cognigni GE, Pasqui F, Pagotto U & Pasquali R. Prominent role of low HDLcholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. Nutrition, Metabolism, and Cardiovascular Diseases 2009 19 797-804. (doi:10.1016/j.numecd.2009.01.007)
30. Amato MC, Verghi M, Galluzzo A & Giordano C. The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Human Reproduction 2011 26 1486-1494. (doi:10.1093/humrep/der088)
31. Brown ZA, Louwers YV, Fong SL, Valkenburg O, Birnie E, de Jong FH, Fauser BC & Laven JS. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertility and Sterility 2011 96 1259-1265. (doi:10.1016/j.fertnstert.2011.09.002)
32. Pasquali R & Gambineri A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Annals of the New York Academy of Sciences 2006 1092 158-174. (doi:10.1196/annals.1365.014)
33. Pasquali R & Gambineri A. Glucose intolerance states in women with polycystic ovary syndrome. Journal of Endocrinological Investigation 2013 36 648-653. (doi:10.1007/BF03346757)
34. Tomlinson J, Millward A, Stenhouse E & Pinkney J. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? Diabetic Medicine 2010 27 498-515. (doi:10.1111/j.1464-5491.2010.02994.x)
35. Legro RS, Kunselman AR, Dodson WC & Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. Journal of Clinical Endocrinology and Metabolism 1999 84 165-169.
36. Legro RS, Gnatuk CL, Kunselman AR & Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. Journal of Clinical Endocrinology and Metabolism 2005 90 3236-3242. (doi:10.1210/jc.2004-1843)
37. Gambineri A, Patton L, Altieri P, Pagotto U, Pizzi C, Manzoli L & Pasquali R. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes 2012 61 2369-2374. (doi:10.2337/db11-1360)
38. Goodarzi MO, Quiñones MJ, Azziz R, Rotter JI, Hsueh WA & Yang H. Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertility and Sterility 2005 84 766-769. (doi:10.1016/j.fertnstert.2005.03.051)
39. Ezeh U, Yildiz BO & Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2013 98 E1088-E1096. (doi:10.1210/jc.2013-1295)
40. Urbanek M. The genetics of the polycystic ovary syndrome. Nature Clinical Practice. Endocrinology & Metabolism 2007 3 103-111. (doi:10.1038/ncpendmet0400)
41. Escobar-Morreale HF, Luque-Ramírez M & San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocrine Reviews 2005 26 251-282.
42. Abbott DH, Bruns CM, Barnett DK & Dumesic DA. Fetal programming of polycystic ovary syndrome. In Polycystic Ovary Syndrome, pp 262-287. Eds G Kovacs & R Norman, Cambridge: Cambridge University Press, 2007.
43. Abbott DH, Barnett DK, Bruns CM & Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Human Reproduction Update 2005 11 357-374. (doi:10.1093/humupd/dmi013)
44. Maliqueo M, Lara HE, Sanchez F, Echiburu B, Crisosto N & Sir-Petermann T. Placental steroidogenesis in pregnant women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2013 166 151-155. (doi:10.1016/j.ejogrb.2012.10.015)
45. Carroll J, Saxena R & Welt CK. Environmental and genetic factors influence age at menarche in women with polycystic ovary syndrome. Journal of Pediatric Endocrinology & Metabolism 2012 25 459-466. (doi:10.1515/jpem-2012-0047)
46. Vanky E, Nordskar J, Leithe H, Hjorth-Hansen A, Martinussen M & Carlsen S. Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow-up study of a randomized controlled trial on metformin versus placebo. British Journal of Obstetrics and Gynaecology 2012 119 1403-1409. (doi:10.1111/j.1471-0528.2012.03449.x)
47. Stanczyk FZ. Diagnosis of hyperandrogenism: biochemical criteria. Best Practice & Research. Clinical Endocrinology & Metabolism 2006 20 177-191. (doi:10.1016/j.beem.2006.03.007)
48. Rosner W, Auchus RJ, Azziz R, Sluss PM & Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. Journal of Clinical Endocrinology and Metabolism 2007 92 405-413. (doi:10.1210/jc.2006-1864)
49. Rosner W & Vesper H. Toward excellence in testosterone testing: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2010 95 4542-4548. (doi:10.1210/jc.2010-1314)
50. Janse F, Eijkemans MJ, Goverde AJ, Lentjes EG, Hoek A, Lambalk CB, Hickey TE, Fauser BC & Norman RJ. Assessment of androgen concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results. European Journal of Endocrinology 2011 165 925-933. (doi:10.1530/EJE-11-0482)
51. Moal V, Mathieu E, Reynier P, Malthiery Y & Gallois Y. Low serum testosterone assayed by liquid chromatography-tandem mass spectrometry. Comparison with five immunoassay techniques. Clinica Chimica Acta 2007 386 12-19. (doi:10.1016/j.cca.2007.07.013)
52. Haring R, Hannemann A, John U, Radke D, Nauck M, Wallaschofski H, Owen L, Adaway J, Keevil BG & Brabant G. Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. Journal of Clinical Endocrinology and Metabolism 2012 97 408-415. (doi:10.1210/jc.2011-2134)
53. Vicente FB, Smith FA, Sierra R & Wang S. Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine 2006 44 70-75.
54. O'Reilly MW, Taylor AE, Crabtree NJ, Hughes BA, Capper F, Crowley RK, Stewart PM, Tomlinson JW & Arlt W. Journal of Clinical Endocrinology and Metabolism 2014 99 1027-1036. (doi:10.1210/jc.2013-3399)
55. Allolio B & Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 2006 91 2027-2037. (doi:10.1210/jc.2005-2639)
56. Derksen J, Nagesser SK, Meinders AE, Haak HR & van de Velde CJ. Identification of virilizing adrenal tumors in hirsute women. New England Journal of Medicine 1994 331 968-973. (doi:10.1056/NEJM199410133311502)
57. Pugeat M, Dechaud H, Raverot V, Denuziere A, Cohen R & Boudou P. Recommendations for investigation of hyperandrogenism. Annales d'Endocrinologie 2010 71 2-7. (doi:10.1016/j.ando.2009.12.007)
58. Tsilchorozidou T, Honour JW & Conway GS. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5α-reduction but not the elevated adrenal steroid production rates. Journal of Clinical Endocrinology and Metabolism 2003 88 5907-5913. (doi:10.1210/jc.2003-030240)
59. Vassiliadi DA, Barber TM, Hughes BA, McCarthyMI, Wass JA, Franks S, Nightingale P, Tomlinson JW, Arlt W & Stewart PM. Increased 5α-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2009 94 3558-3566. (doi:10.1210/jc.2009-0837)
60. Fanelli F, Gambineri A, Mezzullo M, Vicennati V, Pelusi C, Pasquali R & Pagotto U. Revisiting hyper- and hypo-androgenism by tandem mass spectrometry. Reviews in Endocrine & Metabolic Disorders 2013 14 185-205. (doi:10.1007/s11154-013-9243-y)
61. Fanelli F, Gambineri A, Belluomo I, Repaci A, Di Lallo VD, Di Dalmazi G, Mezzullo M, Prontera O, Cuomo G, Zanotti L et al. Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women. Journal of Clinical Endocrinology and Metabolism 2013 98 3058-3067. (doi:10.1210/jc.2013-1381)
62. Bhasin S, Jasjua GK, Pencina M, D'Agostino R Sr, Coviello AD, Vasan RS & Travison TG. Sex hormone-binding globulin, but not testosterone, is associated prospectively and independently with incident metabolic syndrome in men: the Framingham Heart Study. Diabetes Care 2011 34 2464-2470. (doi:10.2337/dc11-0888)
63. Glueck CJ, Morrison JA, Daniels S, Wang P & Stroop D. Sex hormonebinding globulin, oligomenorrhea, polycystic ovary syndrome, and childhood insulin at age 14 years predict metabolic syndrome and class III obesity at age 24 years. Journal of Pediatrics 2011 159 308-313. (doi:10.1016/j.jpeds.2011.01.018)
64. Moran LJ, Teede HJ, Noakes M, Clifton PM, Norman RJ & Wittert GA. Sex hormone binding globulin, but not testosterone, is associated with the metabolic syndrome in overweight and obese women with polycystic ovary syndrome. Journal of Endocrinological Investigation 2013 36 1004-1010.
65. Veltman-Verhulst SM, van Haeften TW, Eijkemans MJ, de Valk HW, Fauser BC & Goverde AJ. Sex hormone-binding globulin concentrations before conception as a predictor for gestational diabetes in women with polycystic ovary syndrome. Human Reproduction 2010 25 3123-3128. (doi:10.1093/humrep/deq272)
66. Pasquali R. Obesity and androgens: facts and perspectives. Fertility and Sterility 2006 85 1319-1340. (doi:10.1016/j.fertnstert.2005.10.054)
67. Lim SS, Norman RJ, Davies MJ & Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obesity Reviews 2013 14 95-109. (doi:10.1111/j.1467-789X.2012. 01053.x)
68. Hacihanefioglu B, Aybey B, Hakan Ozon Y, Berkil H & Karsidag K. Association of anthropometric, androgenic and insulin-related features with polymorphisms in exon 8 of SHBG gene in women with polycystic ovary syndrome. Gynecological Endocrinology 2013 29 361-364. (doi:10.3109/09513590.2012.743006)
69. Wickham EP III, Ewens KG, Legro RS, Dunaif A, Nestler JE & Strauss JF III. Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2011 96 E719-E727. (doi:10.1210/jc.2010-1842)
70. Pascale MM, Pugeat M, Roberts M, Rousset H, Dechaud H, Dutrieux- Berger N & Tournaire J. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours. Clinical Endocrinology 1994 41 571-576. (doi:10.1111/j.1365-2265.1994.tb01820.x)
71. Rousset P, Gompel A, Christin-Maitre S, Pugeat M, Hugol D, Ghossian MA & Buy JN. Ovarian hyperthecosis on grayscale and color Doppler ultrasound. Ultrasound in Obstetrics & Gynecology 2008 32 694-699. (doi:10.1002/uog.6131)
72. Pignatelli D. Non-classic adrenal hyperplasia due to the deficiency of 21-hydroxylase and its relation to polycystic ovarian syndrome. Frontiers of Hormone Research 2013 40 158-170.
73. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 3666-3672. (doi:10.1210/jcem.84.10.6079)
74. Ibanez L, Ong KK, Mongan N, Jaaskelainen J, Marcos MV, Hunghes IA, De Zegher F & Dunger DB. Androgen receptor gene CAG repeat polymorphisms in the development of ovarian hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 2003 88 3333-3338. (doi:10.1210/jc.2002-021791)
75. Skrgatic L, Baldani DP, Cerne JZ, Ferk P & Gersak K. CAG repeat polymorphism in androgen receptor gene is not directly associated with polycystic ovary syndrome but influences serum testosterone levels. Journal of Steroid Biochemistry and Molecular Biology 2012 128 107-112. (doi:10.1016/j.jsbmb.2011.11.006)
76. Zhang T, Liang W, Fang M, Yu J, Ni Y & Li Z. Association of the CAG repeat polymorphisms in androgen receptor gene with polycystic ovary syndrome: a systemic review and meta-analysis. Gene 2013 524 161-167. (doi:10.1016/j.gene.2013.04.040)
77. Hurd WW, Abdel-Rahman MY, Ismail SA, Abdellah MA, Schmotzer CL & Sood A. Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome. Fertility and Sterility 2011 96 1043-1047. (doi:10.1016/j.fertnstert.2011.07.002)
78. Lerchbaum E, Schwetz V, Giuliani A & Obermayer-Pietsch B. Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method. Human Reproduction 2013 28 2537-2544. (doi:10.1093/humrep/det255)
79. Veltman-Verhulst SM, Goverde AJ, van Haeften TW & Fauser BC. Fasting glucose measurement as a potential first step screening for glucose metabolism abnormalities in women with anovulatory polycystic ovary syndrome. Human Reproduction 2013 28 2228-2234. (doi:10.1093/humrep/det226)
80. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW & Nestler JE. Glucose intolerance in polycystic ovary syndrome - a position statement of the Androgen Excess Society. Journal of Clinical Endocrinology and Metabolism 2007 92 4546-4556. (doi:10.1210/jc.2007-1549)
81. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E & Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism 2010 95 2038-2049. (doi:10.1210/jc.2009-2724)
82. Diamanti-Kandarakis E, Kouli C, Alexandraki K & Spina G. Failure in mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2004 83 1273-1276. (doi:10.1210/jc.2003-031205)
83. Hendriks ML, Brouwer J, Hompes PG, Homburg R & Lambalk CB. LH as a diagnostic criterion for polycystic ovary syndrome in patients with WHO II oligo/amenorrhoea. Reproductive Biomedicine Online 2008 16 765-771. (doi:10.1016/S1472-6483(10)60140-X)
84. Arroyo A, Laughlin GA, Morales AJ & Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. Journal of Clinical Endocrinology and Metabolism 1997 82 3728-3733.
85. Deligeoroglou E, Athanasopoulos N, Tsimaris P, Dimopoulos KD, Vrachnis N & Creatsas G. Evaluation and management of adolescent amenorrhea. Annals of the New York Academy of Sciences 2010 1205 23-32. (doi:10.1111/j.1749-6632.2010.05669.x)
86. Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P & Grayson K. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Human Reproduction 2013 28 1077-1083. (doi:10.1093/humrep/det015)
87. Pawelczak M, Kenigsberg L, Milla S, Liu YH & Shah B. Elevated serum anti-Mullerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features. Journal of Pediatric Endocrinology & Metabolism 2012 25 983-989. (doi:10.1515/jpem-2012-0013)
88. Pellatt L, Rice S & Mason HD. Anti-Mullerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction 2010 139 825-833. (doi:10.1530/REP-09-0415)
89. Iliodromiti S, Kelsey TW, Anderson RA & Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. Journal of Clinical Endocrinology and Metabolism 2013 98 3332-3340. (doi:10.1210/jc.2013-1393)
90. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S & Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. American Journal of Physiology. Endocrinology and Metabolism 2009 296 E238-E243. (doi:10.1152/ajpendo.90684.2008)
91. Catteau-Jonard S, Bancquart J, Poncelet E, Lefebvre-Maunoury C, Robin G & Dewailly D. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome? Ultrasound in Obstetrics & Gynecology 2012 40 223-229. (doi:10.1002/uog.11202)
92. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH & Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. Journal of Clinical Endocrinology and Metabolism 2004 89 318-323. (doi:10.1210/jc.2003-030932)
93. Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ & EscobarMorreale HF. Definition and significance of polycystic ovarian morphology: a task force from the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update 2014 20 334-352. (doi:10.1093/humupd/dmt061)
94. Stener-Victorin E, Holm G, Labrie F, Nilsson L, Janson PO & Ohlsson C. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? Journal of Clinical Endocrinology and Metabolism 2010 95 810-819. (doi:10.1210/jc.2009-1908)
95. Thomson RL, Spedding S, Brinkworth GD, Noakes M & Buckley JD. Seasonal effects on vitamin D status influence outcomes of lifestyle intervention in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility 2013 99 1779-1785. (doi:10.1016/j. fertnstert.2012.12.042)
96. Li HW, Brereton RE, Anderson RA, Wallace AM & Ho CK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 2011 60 1475-1481. (doi:10.1016/j.metabol.2011.03.002)
97. Krul-Poel YH, Snackey C, Louwers Y, Lips P, Lambalk CB, Laven JS & Simsek S. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. European Journal of Endocrinology 2013 169 853-865. (doi:10.1530/EJE-13-0617)
98. Perez-Fernandez R, AlonsoM, Segura C, Munoz I, Garcia-Caballero T & Diguez C. Vitamin D receptor gene expression in human pituitary gland. Life Sciences 1997 60 35-42. (doi:10.1016/S0024- 3205(96)00586-3)
99. Zarnani AH, Shahbazi M, Salek-Moghaddam A, Zareie M, Tavakoli M, Ghasemi J, Rezania S,Moravej A, Torkabadi E, Rabbani H et al. Vitamin D3 receptor is expressed in the endometrium of cycling mice throughout the estrous cycle. Fertility and Sterility 2010 93 2738-2743. (doi:10.1016/j.fertnstert.2009.09.045)
100. Stumpf WE, Sar M, Reid FA, Tanaka Y & DeLuca HF. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979 206 1188-1190. (doi:10.1126/science.505004)
101. Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S & Mason H. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. Journal of Clinical Endocrinology and Metabolism 2007 92 240-245. (doi:10.1210/jc.2006-1582)
102. Lebeurrier N, Launay S, Macrez R, Maubert E, Legros H, Leclerc A, Jamin SP, Picard JY, Marret S, Laudenbach V et al. Anti-Mullerianhormone- dependent regulation of the brain serine-protease inhibitor neuroserpin. Journal of Cell Science 2008 121 3357-3365. (doi:10.1242/jcs.031872)
103. Wang PY, Protheroe A, Clarkson AN, Imhoff F, Koishi K & McLennan IS. Müllerian inhibition substance contributes to sex-linked biases in the brain and behaviour. PNAS 2009 106 7203-7208. (doi:10.1073/pnas.0902253106)
104. Wojtusik J & Johnson PA. Vitamin D regulates anti-Mullerian hormone expression in granulosa cells of the hen. Biology of Reproduction 2012 86 91. (doi:10.1095/biolreprod.111.094110)
105. Dicken CL, Israel DD, Davis JB, Sun Y, Shu J, Hardin J & Neal-Perry G. Peripubertal vitamin D(3) deficiency delays puberty and disrupts the estrous cycle in adult female mice. Biology of Reproduction 2012 87 51. (doi:10.1095/biolreprod.111.096511)
106. Diamanti-Kandarakis E, Katsikis I, Piperi C, Kandaraki E, Piouka A, Papavassiliou AG & Panidis D. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome. Clinical Endocrinology 2008 69 634-641. (doi:10.1111/j.1365-2265.2008.03247.x)
107. Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, Kandaraki E, Levidou G, Papalois A, Patsouris E & Papavassiliou AG. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. Journal of Molecular Medicine 2007 85 1413-1420. (doi:10.1007/s00109-007-0246-6)
108. Merhi Z, Irani M, Doswell AD & Ambroggio J. Follicular fluid receptor for advanced glycation end-products (sRAGE): a potential indicator of ovarian reserve. Journal of Clinical Endocrinology and Metabolism 2014 29 135-145.
109. Insenser M & Escobar-Morreale HF. Application of proteomics to the study of polycystic ovary syndrome. Journal of Endocrinological Investigation 2011 34 869-875.
110. Galazis N, Afxentiou T, Xenophontos M, Diamanti-Kandarakis E & Atiomo W. Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome. European Journal of Endocrinology 2013 168 R33-R43. (doi:10.1530/EJE-12-0718)
111. Corton M, Botella-Carretero JI, Lopez JA, Camafeita E, San Millan JL, Escobar-Morreale HF & Peral B. Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. Human Reproduction 2008 23 651-661. (doi:10.1093/humrep/dem380)
112. Inserser M, Montes-Nieto R, Murri M & Escobar-Morreale HF. Proteomic and metabolomic approaches to the study of polycystic ovary syndrome. Molecular and Cellular Endocrinology 2013 370 65-77. (doi:10.1016/j.mce.2013.02.009)
113. Meng Y, Liu XH, Ma X, Shen Y, Fan L, Leng J, Liu JY & Sha JH. The protein profile of mouse mature cumulus-oocyte complex. Biochimica et Biophysica Acta 2007 1774 1477-1490. (doi:10.1016/j.bbapap.2007.08.026)
114. Balen AH, Laven JS, Tan SL & Dewailly D. Ultrasound assessment of the polycystic ovary syndrome: international consensus definitions. Human Reproduction Update 2003 9 505-514. (doi:10.1093/humupd/dmg044)
115. Johnstone EB, Rosen MP, Neril R, Trevithick D, Sternfeld B, Murphy R, Addauan-Andersen C, McConnell D, Pera RR & Cedars MI. The polycystic ovary post-Rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. Journal of Clinical Endocrinology and Metabolism 2010 95 965-4972. (doi:10.1210/jc.2010-0202)
116. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A & Catteau-Jonard S. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Human Reproduction 2011 26 3123-3129. (doi:10.1093/humrep/der297)
117. Lujan ME, Jarrett BY, Brooks ED, Reines JK, Peppin AK, Muhn N, Haider E, Pierson RA & Chizen DR. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Human Reproduction 2013 28 1361-1368. (doi:10.1093/humrep/det062)
118. Deb S, Campbell BK, Clewes JS & Raine-Fenning NJ. Quantitative analysis of antral follicle number and size: a comparison of two-dimensional and automated three-dimensional ultrasound techniques. Ultrasound in Obstetrics & Gynecology 2010 35 354-360. (doi:10.1002/uog.7505)
119. Deb S, Jayaprakasan K, Campbell BK, Clewes JS, Johnson IR & Raine-Fenning NJ. Intraobserver and interobserver reliability of automated antral follicle counts made using three-dimensional ultrasound and SonoAVC. Ultrasound in Obstetrics & Gynecology 2009 33 477-483. (doi:10.1002/uog.6310)
120. Jayaprakasan K, Walker KF, Clewes JS, Johnson IR & Raine-Fenning NJ. The interobserver reliability of off-line antral follicle counts made from stored three-dimensional ultrasound data: a comparative study of different measurement techniques. Ultrasound in Obstetrics & Gynecology 2007 29 335-341. (doi:10.1002/uog.3913)
121. Fulghesu AM, Angioni S, Frau E, Belosi C, Apa R, Mioni R, Xamin N, Capobianco GP, Dessole S, Fruzzetti F et al. Ultrasound in polycystic ovary syndrome - the measuring of ovarian stroma and relationship with circulating androgens: results of a multicentric study. Human Reproduction 2007 22 2501-2508. (doi:10.1093/humrep/dem202)
122. Lim SS, Davies MJ, Norman RJ & Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2012 18 618-637. (doi:10.1093/humupd/dms030)
123. Diamanti-Kandarakis E, Christakou C & Marinakis E. Phenotypes and environmental factors: their influence in PCOS. Current Pharmaceutical Design 2012 18 270-282. (doi:10.2174/138161212799040457)
124. Morgan CL, Jenkins-Jones S, Currie CJ & Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. Journal of Clinical Endocrinology and Metabolism 2012 97 3251-3260. (doi:10.1210/jc.2012-1690)
125. Manneras-Holm L, Leonhardt H, Kullberg J, Jennische E, Oden A, Hilm G, Hellstrom M, Lonn L, Olivecrona G, Stener-Victorin E et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. Journal of Clinical Endocrinology and Metabolism 2011 96 E304-E311. (doi:10.1210/jc.2010-1290)
126. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine 2002 8 1288-1295. (doi:10.1038/nm788)
127. O'Connor A, Phelan N, Tun TK, Boran G, Gibney J & Roche HM. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. Journal of Clinical Endocrinology and Metabolism 2010 95 1378-1385. (doi:10.1210/jc.2009-1557)
128. Yildiz BO. Polycystic ovary syndrome: is obesity a symptom? Women's Health 2013 9 505-507. (doi:10.2217/whe.13.53)
129. Villa J & Pratley R. Adipose tissue dysfunction in polycystic ovary syndrome. Current Diabetes Reports 2011 11 179-184. (doi:10.1007/s11892-011-0189-8)
130. Repaci A, Gambineri A & Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Molecular and Cellular Endocrinology 2011 15 30-41. (doi:10.1016/j.mce.2010.08.002)
131. Corton M, Botella-Carretero JI, Benguría A, Villuendas G, Zaballos A, San Millán JL, Escobar-Morreale HF & Peral B. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2007 92 328-337. (doi:10.1210/jc.2006-1665)
132. Xu XF, De Pergola G & Bjorntorp P. Testosterone increases lipolysis and the number of b-adrenoceptors in male rat adipocytes. Endocrinology 1991 128 379-382. (doi:10.1210/endo-128-1-379)
133. Tao T, Li S, Zhao A, Zhang Y & Liu W. Expression of the CD11c gene in subcutaneous adipose tissue is associated with cytokine level and insulin resistance in women with polycystic ovary syndrome. European Journal of Endocrinology 2012 167 705-713. (doi:10.1530/EJE-12-0340)
134. Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A & White DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2001 86 1175-1180.
135. Nandalike K, Strauss T, Agarwal C, Coupey SM, Sin S, Rajpathak S, Cohen HW & Arens R. Screening for sleep-disordered breathing and excessive daytime sleepiness in adolescent girls with polycystic ovarian syndrome. Journal of Pediatrics 2011 159 591-596. (doi:10.1016/j.jpeds.2011.04.027)
136. Mokhlesi B, Scoccia B, Mazzone T & Sam S. Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women. Fertility and Sterility 2012 97 786-791. (doi:10.1016/j.fertnstert.2011.12.024)
137. Tasali E, Van Cauter E, Hoffman L & Ehrmann DA. Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2008 93 3878-3884. (doi:10.1210/jc.2008-0925)
138. Tasali E, Chapotot F, Leproult R, Whitmore H & Ehrmann DA. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2011 96 365-374. (doi:10.1210/jc.2010-1187)
139. Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M, Kimmig R, Benson S, Balamitsa E & Elsenbruch S. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. European Journal of Endocrinology 2005 153 853-860. (doi:10.1530/eje.1.02024)
140. Elsenbruch S, Hahn S, Kowalsky D, Offner AH, Schedlowsky M, Mann K & Jansen O. Quality of life, psychological wellbeing and sexual satisfaction in women with PCOS. Journal of Clinical Endocrinology and Metabolism 2003 88 5801-5807. (doi:10.1210/jc.2003-030562)
141. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ & Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertility and Sterility 2007 87 1369-1376. (doi:10.1016/j.fertnstert.2006.11.039)
142. Dokras A, Clifton S, Futterweit W & Wild R. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstetrics and Gynecology 2011 117 145-152. (doi:10.1097/AOG. 0b013e318202b0a4)
143. Coffey S, Bano G & Mason H. Health-related quality of life in women with PCOS: a comparison with the general population using the PCOS questionnaire and the SF-36. Gynecological Endocrinology 2006 22 80-86. (doi:10.1080/09513590600604541)
144. Barnard L, Ferriday D, Guenther N, Strauss B, Balen AH & Dye L. Quality of life and psychological well being inpolycystic ovary syndrome. Human Reproduction 2007 22 2279-2286. (doi:10.1093/humrep/dem108)
145. Moran LJ, Deeks AA, Gibson-Helm ME & Teede HJ. Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. Human Reproduction 2012 27 2082-2088. (doi:10.1093/humrep/des114)
146. Zigmond AS & Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica 1983 67 361-370. (doi:10.1111/j.1600-0447.1983.tb09716.x)
147. Rosenberg's Self-Esteem Scale & Rosenberg M. Society and the adolescent self-image. Princeton, NJ: Princeton University Press, 1965.
148. Beck AT, Epstein N, Brown G & Steer RA. An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology 1988 56 893-897. (doi:10.1037/0022-006X.56.6.893)
149. Beck AT, Ward CH, Mendelson M & Erbaugu J. An inventory for measuring depression. Archives of General Psychiatry 1961 4 561-571. (doi:10.1001/archpsyc.1961.01710120031004)
150. Symptom Checklist 90 (SCL-90-R). Symptoms Checklist-90 - revised. In Handbook of Psychiatric Measures. American Psychiatric Association, 2000.
151. Ware J & Sherbourne C. The MOS 36-Item Short Form Health Survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992 30 473-483. (doi:10.1097/00005650-199206000-00002)
152. Jones G, Benes K, Clark T, Denham R, Holder M, Haynes T, Mulgrew N, Shepherd K, Wilkinson V, Singh M et al. The PCOS health-related quality of life questionnaire (PCSOQ): a validation. Human Reproduction 2004 19 371-377. (doi:10.1093/humrep/deh048)
153. Ching H, Burke V & Stuckey B. Quality of life and psychological morbidity in women with PCOS: BMI, age, and the provision of patient information are significant modifiers. Clinical Endocrinology 2007 66 373-379. (doi:10.1111/j.1365-2265.2007.02742.x)
154. Hahn S, Benson S, Elsenbruch S, Pleger K, Tan S, Mann K, Schedlowski M, van Halteren W, Kimmig R & Janssen O. Metformin treatment of PCOS improves health related quality of life emotional distress and sexuality. Human Reproduction 2006 21 1925-1934. (doi:10.1093/humrep/del069)
155. Elsenbruch S, Benson S, Hahn S, Tan S, Mann K, Pleger K, Kimmig R & Jansen O. Determinants of emotional distress in women with PCOS. Human Reproduction 2006 21 1092-1099. (doi:10.1093/humrep/dei409)
156. Van Wely M, Bayram N, Bossuyt P & Van der Veen F. Laparoscopic electrocautery of the ovaries versus recombinant FSH in clomiphene citrate-resistant PCOS. Impact on women's health related quality of life. Human Reproduction 2004 19 2244-2250. (doi:10.1093/humrep/deh406)
157. de Niet JE, de Koning CM, Pastoor H, Duivenvoorden HJ, Valkenburg O, Ramakers MJ, Passchier J, de Klerk C & Laven JS. Psychological well-being and sexarche in women with polycystic ovary syndrome. Human Reproduction 2010 25 1497-1503. (doi:10. 1093/humrep/deq068)
158. Lipton M, Sherr L, Elford J, Rustin M & Clayton W. Women living with facial hair: the psychological and behavioural burden. Journal of Psychosomatic Research 2006 61 161-168. (doi:10.1016/j.jpsychores.2006.01.016)
159. Tan S, Hahn S, Benson S, Janssen O, Dietz T, Kimmig R, Hesse- Huissain J, Mann K, Schedlowsky M, Arck P et al. Psychological implications of infertility in women with PCOS. Human Reproduction 2008 23 2064-2071. (doi:10.1093/humrep/den227)
160. Cinar N, Kizilarslanoglu MC, Harmanci A, Aksoy DY, Bozdag G, Demir B & Yildiz BO. Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome. Human Reproduction 2011 26 3339-3345. (doi:10.1093/humrep/der338)
161. ManssonM, Holte J, Landin-Wilhemsen K, Dahlgren E, Johansson A & Landen M. Women with polycystic ovary syndrome are often depressed or anxious: a case control study. Psychoneuroendocrinology 2008 33 1132-1138. (doi:10.1016/j.psyneuen.2008.06.003)
162. Açaz G, Albayrak E, Acmaz B, Başr M, Soyak M, Zararsiz G & Müderris Ipek. Level of anxiety, depression, self-esteem, social anxiety, and quality of life among the women with polycystic ovary syndrome. Scientific World Journal 2013 851815. (doi:10.1155/2013/851815)
163. Barry J, Kuczmierczyk A & Hardiman P. Anxiety and depression in PCOS: a systematic review and meta-analysis. Human Reproduction 2011 26 2442-2451. (doi:10.1093/humrep/der197)
164. Alvarez-Blasco F, Luque-Ramírez M & Escobar-Morreale HF. Obesity impairs general health-related quality of life (HR-QoL) in premenopausal women to a greater extent than polycystic ovary syndrome (PCOS). Clinical Endocrinology 2010 73 595-601. (doi:10.1111/j.1365-2265.2010.03842.x)
165. Cinar N, Harmanci A, Demir B & Yildiz BO. Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study. Human Reproduction 2012 27 1840-1845. (doi:10.1093/humrep/des113)
166. Thomson RL, Buckley JD, Lim SS, NoakesM, Clifton PM, Norman RJ & Brinkworth GD. Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility 2010 94 1812-1816. (doi:10.1016/j.fertnstert.2009.11.001)
167. Livadas S, Chaskou S, Kandaraki AA, Skourletos G, Economou F, Christou M, Boutzios G, Karachalios A, Zerva A, Xyrafis X et al. Anxiety is associated with hormonal and metabolic profile in women with polycystic ovarian syndrome. Clinical Endocrinology 2011 75 698-670. (doi:10.1111/j.1365-2265.2011.04122.x)
168. Jedel E, Gustafson D, Waern M, Sverrisdottir YB, Landén M, Janson PO, Labrie F, Ohlsson C & Stener-Victorin E. Sex steroids, insulin sensitivity and sympathetic nerve activity in relation to affective symptoms in women with polycystic ovary syndrome. Psychoneuroendocrinology 2011 36 1470-1479. (doi:10.1016/j.psyneuen.2011.04.001)
169. Benson S, Arck PC, Tan S, Hahn S, Mann K, Rifaie N, Janssen OE, Schedlowski M & Elsenbruch S. Disturbed stress responses in women with polycystic ovary syndrome. Psychoneuroendocrinology 2009 34 727-735. (doi:10.1016/j.psyneuen.2008.12.001)
170. Sverrisdóttir YB, Mogren T, Kataoka J, Janson PO & Stener-Victorin E. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? American Journal of Physiology. Endocrinology and Metabolism 2008 294 E576-E581. (doi:10.1152/ajpendo.00725.2007)
171. Kowalczyk R, Skrzypulec V, Lew-Starowicz Z, Nowosielski K, Grabski B & Merk W. Psychological gender of patients with polycystic ovary syndrome. Acta Obstetricia et Gynecologica Scandinavica 2012 91 710-714. (doi:10.1111/j.1600-0412.2012.01408.x)
172. Carmina E, Campagna AM & Lobo RA. Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk factors. Human Reproduction 2013 28 2245-2252. (doi:10.1093/humrep/det119)
173. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H & Connell JM. Altered vascular function in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 742-746. (doi:10.1210/jcem.87.2.8199)
174. Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterkis T, Lekakis J & Panidis S. Inflammatory and endothelial markers in women with polycystic ovary syndrome. European Journal of Clinical Investigation 2006 36 691-697. (doi:10.1111/j.1365-2362.2006.01712.x)
175. Legro RS, Kunselman AR & Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. American Journal of Medicine 2001 111 607-613. (doi:10.1016/S0002-9343(01)00948-2)
176. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH & Laven JS. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. Journal of Clinical Endocrinology and Metabolism 2008 93 470-476. (doi:10.1210/jc.2007-1756)
177. Joharatnam J, Barber TM, Webber L, Conway GS, McCarthy MI & Franks S. Determinants of dyslipidaemia in probands with polycystic ovary syndrome and their sisters. Clinical Endocrinology 2011 74 714-719. (doi:10.1111/j.1365-2265.2011.03983.x)
178. Hudecova M, Holte J, Olovsson M, Larsson A, Berne C & Sundstrom- Poromaa I. Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term followup. Fertility and Sterility 2011 96 1271-1273. (doi:10.1016/j.fertnstert.2011.08.006)
179. Macut D, Panidis D, Glisić B, Spanos N, Petakov M, BjekićJ, StanojlovićO, Rousso D, Kourtis A, BozićI et al. Lipid and lipoprotein profile in women with polycystic ovary syndrome. Canadian Journal of Physiology and Pharmacology 2008 86 199-204. (doi:10.1139/Y08-014)
180. Glintborg D, Mumm H, Hougaard D, Ravn P & Andersen M. Ethnic differences in Rotterdam criteria and metabolic risk factors in a multiethnic group of women with PCOS studied in Denmark. Clinical Endocrinology 2010 73 732-738. (doi:10.1111/j.1365-2265.2010. 03873.x)
181. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA & Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends in Endocrinology and Metabolism 2007 18 280-285. (doi:10.1016/j.tem.2007.07.004)
182. Pirwany IR, Fleming R, Greer IA, Packard CJ & Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clinical Endocrinology 2001 54 447-453. (doi:10.1046/j.1365-2265.2001.01228.x)
183. Macut D, DamjanovićS, Panidis D, Spanos N, GlišićB, Petakov M, Rousso D, Kourtis A, Bjekić J & Milić N. Oxidised low-density lipoprotein concentrations: early marker of an altered lipid metabolism in young women with PCOS. European Journal of Endocrinology 2006 155 131-136. (doi:10.1530/eje.1.02187)
184. Macut D, Simic T, Lissounov A, Pljesa-Ercegovac M, Bozic I, Djukic T, Bjekic-Macut J, Matic M, Petakov M, Suvakov S et al. Insulin resistance in non-obese women with polycystic ovary syndrome: relation to byproducts of oxidative stress. Experimental and Clinical Endocrinology & Diabetes 2011 119 451-455. (doi:10.1055/s-0031-1279740)
185. Victor M, Rocha M, Banuls C, Sanchez-Serrano M, Sola E, Gomez M & Hernandez-Mijares A. Mitochondrial complex I impairment in leukocytes from polycystic ovary syndrome patients with insulin resistance. Journal of Clinical Endocrinology and Metabolism 2009 94 3505. (doi:10.1210/jc.2009-0466)
186. Rabol R, Svendsen PF, Skovbro M, Boushel R, Schjerling P, Nilas L, Madsbad S & Dela F. Skeletal muscle mitochondrial function in polycystic ovarian syndrome. European Journal of Endocrinology 2011 165 631-637. (doi:10.1530/EJE-11-0419)
187. Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M & Escobar- Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Human Reproduction Update 2013 19 268-288. (doi:10.1093/humupd/dms059)
188. Kodaman PH & Duleba AJ. Statins: do they have potential in the treatment of polycystic ovary syndrome? Seminars in Reproductive Medicine 2008 26 127-138. (doi:10.1055/s-2007-992933)
189. Ou X-H, Li S, Wang Z-B, Li M, Quan S, Xing F, Guo G, Chao S-B, Chen Z, Liang X-W et al. Maternal insulin resistance causes oxidative stress and mitochondrial dysfunction in mouse oocytes. Human Reproduction 2012 27 2130-2145. (doi:10.1093/humrep/des137)
190. Boutzios G, Livadas S, Piperi C, Vitoratos N, Adamopoulos C, Hassiakos D, Iavazzo C & Diamanti-Kandarakis E. Polycystic ovary syndrome offspring display increased oxidative stress markers comparable to gestational diabetes offspring. Fertility and Sterility 2013 99 943-950. (doi:10.1016/j.fertnstert.2012.10.050)
191. Christakou C, Economou F, Livadas S, Piperi C, Adamopoulos C, Marinakis E & Diamanti-Kandarakis E. Strong and positive association of endothelin-1 with AGEs in PCOS: a causal relationship or a bystander? Hormones 2011 10 292-297. (doi:10.14310/horm.2002.1320)
192. Tantalaki E, Piperi C, Livadas S, Kollias A, Adamopoulos C, Koulouri A, Christakou C & Diamanti-Kandarakis E. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones 2014 13 65-73.
193. Sprung VS, Atkinson G, Cuthbertson DJ, Pugh CJ, Aziz N, Cable NT & Jones H. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies. Clinical Endocrinology 2012 78 438-446. (doi:10.1111/j.1365-2265.2012.04490.x)
194. Bajuk Studen K, Jensterle Sever M & Pfeifer M. Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome. Frontiers of Hormone Research 2013 40 64-82.
195. Ketel IJ, Stehouwer CD, Henry RM, Serné EH, Hompes P, Homburg R, Smulders YM & Lambalk CB. Greater arterial stiffness in polycystic ovary syndrome (PCOS) is an obesity - but not a PCOS-associated phenomenon. Journal of Clinical Endocrinology and Metabolism 2010 95 4566-4575. (doi:10.1210/jc.2010-0868)
196. Ketel IJ, SernéEH, Ijzerman RG, Korsen TJ, Twisk JW, Hompes PG, Smulders YM, Homburg R, Vorstermans L, Stehouwer CD et al. Insulin-induced capillary recruitment is impaired in both lean and obese women with PCOS. Human Reproduction 2011 26 3130-3137. (doi:10.1093/humrep/der296)
197. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE & Manson JE. Menstrual cycle irregularity and risk for future cardiovascular disease. Journal of Clinical Endocrinology and Metabolism 2002 87 2013-2017. (doi:10.1210/jcem.87.5.8471)
198. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. Journal of Clinical Endocrinology and Metabolism 2008 93 1276-1284. (doi:10.1210/jc.2007-0425)
199. Wild S, Pierpoint T, McKeigue P & Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clinical Endocrinology 2000 52 595-600. (doi:10.1046/j.1365-2265.2000.01000.x)
200. Wang ET, Cirillo PM, Vittinghoff E, Bibbins-Domingo K, Cohn BA & Cedars MI. Menstrual irregularity and cardiovascular mortality. Journal of Clinical Endocrinology and Metabolism 2011 96 E114-E118. (doi:10.1210/jc.2010-1709)
201. de Groot PC, Dekkers OM, Romijn JA, Dieben SWM & Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Human Reproduction Update 2011 17 495-500. (doi:10.1093/humupd/dmr001)
202. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, ShepardMK & Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001 103 1410-1415. (doi:10.1161/01.CIR. 103.10.1410)
203. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos GP, Tsatsoulis A & Michalis LK. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 5088-5095. (doi:10.1210/jc.2005-0151)
204. Meyer ML, Malek AM, Wild RA, Korytkowski MT & Talbott EO. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2012 18 112-126. (doi:10.1093/humupd/dmr046)
205. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF II & Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 2562-2568. (doi:10.1210/jc.2003-030334)
206. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE & Kuller LH. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 2414-2421. (doi:10.1161/01.ATV.20.11.2414)
207. Kuchenbecker WK, Groen H, van Asselt SJ, Bolster JH, Zwerver J, Slart RH, Jagt Vd, Muller Kobold AC, Wolffenbuttel BH, Land JA et al. In women with polycystic ovary syndrome and obesity, loss of intraabdominal fat is associated with resumption of ovulation. Human Reproduction 2011 26 2505-2512. (doi:10.1093/humrep/der229)
208. Harrison CL, Lombard CB, Moran LJ & Teede HJ. Exercise therapy in polycystic ovary syndrome: a systematic review. Human Reproduction Update 2011 17 171-183. (doi:10.1093/humupd/dmq045)
209. Harrison CL, Stepto NK, Hutchison SK & Teede HJ. The impact of intensified exercise training on insulin resistance and fitness in overweight and obese women with and without polycystic ovary syndrome. Clinical Endocrinology 2012 76 351-357. (doi:10.1111/j.1365-2265.2011.04160.x)
210. Hutchison SK, Stepto NK, Harrison CL, Moran LJ, Strauss BJ & Teede HJ. Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2011 96 E48-E56. (doi:10.1210/jc.2010-0828)
211. Moran LJ, Pasquali R, Teede HJ, Hoeger KM & Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertility and Sterility 2009 92 1966-1982. (doi:10.1016/j.fertnstert.2008.09.018)
212. Domecq JP, Prutsky G, Mullan RJ, Hazem A, Sundaresh V, Elamin MB, Phung OJ, Wang A, Hoeger K, Pasquali R et al. Lifestyle modification programs in polycystic ovary syndrome: systematic review and metaanalysis. Journal of Clinical Endocrinology and Metabolism 2013 98 4655-4663. (doi:10.1210/jc.2013-2385)
213. Pasquali R, Gambineri A, Cavazza C, Ibarra-Gasparini D, Ciampaglia W, Cognigni GE & Pagotto U. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. European Journal of Endocrinology 2011 164 53-60. (doi:10.1530/EJE-10-0692)
214. Ayyad C & Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obesity Reviews 2000 1 113-119. (doi:10.1046/j.1467-789x.2000.00019.x)
215. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J & San Millán JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. Journal of Clinical Endocrinology and Metabolism 2005 90 6364-6369. (doi:10.1210/jc.2005-1490)
216. Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, Norman RJ & Costello MF. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Medical Journal of Australia 2011 195 S65-S112. (doi:10.5694/mja11.10915)
217. Legro RS, Dodson WC, Gnatuk CL, Estes SJ, Kunselman AR, Meadows JW, Kesner JS, Krieg EF, Rogers AM, Haluck RS et al. Effects of gastric bypass surgery on female reproductive function. Journal of Clinical Endocrinology and Metabolism 2012 97 4540-4548. (doi:10.1210/jc.2012-2205)
218. Malik SM & Traub ML. Defining the role of bariatric surgery in polycystic ovarian syndrome patients. World Journal of Diabetes 2012 3 71-79. (doi:10.4239/wjd.v3.i4.71)
219. Gomez-Meade CA, Lopez-Mitnik G, Messiah SE, Arheart KL, Carrillo A & de la Cruz-Muñoz N. Cardiometabolic health among gastric bypass surgery patients with polycystic ovarian syndrome. World Journal of Diabetes 2013 4 64-69. (doi:10.4239/wjd.v4.i3.64)
220. Moran L & Norman R. The effect of bariatric surgery on female reproductive function. Journal of Clinical Endocrinology and Metabolism 2012 97 4352-4354. (doi:10.1210/jc.2012-3606)
221. Diamanti-Kandarakis E, Christakou CD, Kandaraki E & Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. European Journal of Endocrinology 2010 162 193-212. (doi:10.1530/EJE-09-0733)
222. Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B, Wang LY & Zhang SH. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clinical Endocrinology 2011 74 332-339. (doi:10.1111/j.1365-2265.2010.03917.x)
223. Tang TL, Norman RJ, Yasmin E & Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2010 20 CD003053.
224. Du Q, Yang S, Wang YJ, Wu B, Zhao YY & Fan B. Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials. Advances in Therapy 2012 29 763-774. (doi:10.1007/s12325-012-0044-6)
225. Gambineri A, Semple RK, Forlani G, Genghini S, Grassi I, Hyden CS, Pagotto U, O'Rahilly S & Pasquali R. Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin. European Journal of Endocrinology 2008 159 347-353. (doi:10.1530/EJE-08-0272)
226. Nissen SE & Wolski K. Rosiglitazone revisited: an updated metaanalysis of risk for myocardial infarction and cardiovascular mortality. Archives of Internal Medicine 2010 170 1191-1201. (doi:10.1001/archinternmed.2010.207)
227. Mitka M. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety. Journal of the American Medical Association 2013 310 246-247. (doi:10.1001/jama.2013.8141)
228. Flint A, Raben A, Ersbøll AK, Holst JJ & Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International Journal of Obesity and Related Metabolic Disorders 2001 25 781-792. (doi:10.1038/sj.ijo.0801627)
229. Vilsboll T, Christensen M, Junker AE, Knop FK & Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012 344 d7771. (doi:10.1136/bmj.d7771)
230. Torekov SS, Madsbad S & Holst JJ. Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential Obesity Reviews 2011 12 593-601. (doi:10.1111/j.1467-789X.2011. 00860.x)
231. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL & Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulindependent diabetes mellitus. Journal of Clinical Investigation 1995 96 520-527. (doi:10.1172/JCI118064)
232. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D & Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2008 93 2670-2678. (doi:10.1210/jc.2008-0115)
233. Sever MJ, Kocjan T, Pfeifer M, Kravos NA & Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. European Journal of Endocrinology 2014 170 451-459. (doi:10.1530/EJE-13-0797)
234. Baillargeon JP, McClish DK, Essah PA & Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a metaanalysis. Journal of Clinical Endocrinology and Metabolism 2005 90 3863-3870. (doi:10.1210/jc.2004-1958)
235. Merz CN, Johnson BD, Berga S, Braunstein G, Reis SE, Bittner V & WISE Study Group. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Fertility and Sterility 2006 85 1425-1431. (doi:10.1016/j.fertnstert.2006.01.009)
236. Costello M, Shrestha B, Eden J, Sjoblom P & Johnson N. Insulinsensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 2007 CD005552.
237. Nader S & Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Human Reproduction 2007 22 317-322. (doi:10.1093/humrep/del407)
238. Gourdy P. Diabetes and oral contraception. Best Practice & Research. Clinical Endocrinology & Metabolism 2013 27 67-76. (doi:10.1016/j.beem.2012.11.001)
239. Sitruk-Ware R & Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Practice & Research. Clinical Endocrinology & Metabolism 2013 27 13-24. (doi:10.1016/j.beem.2012.09.004)
240. Harmanci A, Cinar N, Bayraktar M & Yildiz BO. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. Clinical Endocrinology 2013 78 120-125. (doi:10.1111/j.1365-2265.2012.04466.x)
241. Bird ST, Hartzema AG, Brophy JM, Etminan M & Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. Canadian Medical Association Journal 2013 185 E115-E120. (doi:10.1503/cmaj.120677)
242. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE & Lokkegard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011 343 d6423. (doi:10.1136/bmj.d6423)
243. Swiglo BA, Cosma M, Flynn DN, Kurtz DM, Labella ML, Mullan RJ, Elamin MB, Erwin DJ & Montori VM. Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. Journal of Clinical Endocrinology and Metabolism 2008 93 1153-1160. (doi:10.1210/jc.2007-2430)
244. Martin K, Chang J, Ehrmann D, Ibanez L, Lobo RA, Rosenfield RL, Shapiro J, Montori VM & Swiglo BA. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 1105-1120. (doi:10.1210/jc.2007-2437)
245. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, Pugeat M, Qiao J, Wijeyaratne CN, Witchel SF et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update 2012 18 146-170. (doi:10.1093/humupd/dmr042)
246. Pasquali R & Gambineri A. Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. European Journal of Endocrinology 2013 170 R75-R90. (doi:10.1530/EJE-13-0585)
247. Dewailly D, Pigny P, Soudan B, Catteau-Jonard S, Decanter C, Poncelet E & Duhamel A. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti- Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 2010 95 4399-4405. (doi:10.1210/jc.2010-0334)
248. Carmina E, Rosato F, Janni A, Rizzo M & Longo RA. Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 2006 91 2-6. (doi:10.1210/jc.2005-1457)
249. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K & Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. Journal of ClinicalEndocrinology and Metabolism 2004 89 453-462. (doi:10.1210/jc.2003-031122)
250. Unluhizarci K, Gokce C, Atmaca H, Bayram F & Kelestimur F. A detailed investigation of hirsutism in a Turkish population: idiopathic hyperandrogenemia as a perplexing issue. Experimental and Clinical Endocrinology & Diabetes 2004 112 504-509. (doi:10.1055/s-2004-821307)
251. Paradisi R & Venturoli S. Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period. European Journal of Endocrinology 2010 163 139-147. (doi:10.1530/EJE-10-0100)
252. Bhattacharya SM& Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertility and Sterility 2012 98 1053-1059. (doi:10.1016/j.fertnstert.2012.06.035)
253. Muderris II II, Bayram F, Sahin Y & Kelestimur F. A comparison between two doses of flutamide (250 mg/d and 500 mg/d) in the treatment of hirsutism. Fertility and Sterility 1997 68 644-647. (doi:10.1016/S0015-0282(97)00266-5)
254. Dikensoy E, Balat O, Pence S, Akcali C & Cicek H. The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. Archives of Gynecology and Obstetrics 2009 279 321-327. (doi:10.1007/s00404-008-0719-z)
255. Ibáñez L, Jaramillo A, Ferrer A & de Zegher F. Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Human Reproduction 2005 20 1833-1836. (doi:10.1093/humrep/dei004)
256. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, Caputo M, Muggeo M & Castello R. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2000 85 89-94.
257. Guido M, Romualdi D, Giuliani M, Siriano R, Selvaggi L, Apa R & Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. Journal of Clinical Endocrinology and Metabolism 2004 89 2817-2823. (doi:10.1210/jc.2003-031158)
258. Palacios S, Foidart JM & Genazzani A. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas 2006 55 297-307. (doi:10.1016/j.maturitas.2006.07.009)
259. Mazza A, Fruci B, Guzzi P, D'Arrico B, Malaquarnera R, Veltri P, Fava A & Belfiore A. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutrition, Metabolism, and Cardiovascular Diseases 2014 24 132-139. (doi:10.1016/j.numecd.2013.04.016)
260. Ganie MA, Khurana ML, Nisar S, Shah PA, Shah ZA, Kulshrestha B, Gupta N, Zargan MA, Wani TA, Mudasir S et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. Journal of Clinical Endocrinology and Metabolism 2013 98 3599-3607. (doi:10.1210/jc.2013-1040)
261. Kelestimur F & Sahin Y. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertility and Sterility 1998 69 66-69. (doi:10.1016/S0015-0282(97)00427-5)
262. Ibáñez L & de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Human Reproduction Update 2006 12 243-252. (doi:10.1093/humupd/dmi054)
263. Escobar-Morreale HF, Samino S, Insenser M, Vinaixa M, Luque- Ramirez M, Lasuncion MA & Correig X. Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clinical Chemistry 2012 58 999-1009. (doi:10.1373/clinchem.2011.176396)
264. Duleba AJ. Medical management of metabolic dysfunction in PCOS. Steroids 2012 77 306-311. (doi:10.1016/j.steroids.2011.11.014)
265. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Martinez- Bermejo E, Lasuncion MA & Escobar-Morreale HF. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2007 92 2453-2461. (doi:10.1210/jc.2007-0282)
266. Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U & Pasquali R. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 2006 91 3970-3980. (doi:10.1210/jc.2005-2250)
267. Sahin Y, Dilber S & Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertility and Sterility 2001 75 496-500. (doi:10.1016/S0015-0282(00)01764-7)
268. Unluhizarci K, Karaca Z & Kelestimur F. Hirsutism - from diagnosis to use of antiandrogens. Frontiers of Hormone Research 2013 40 103-114.
269. Wagner R, Tomich J & Grande D. Electrolysis and thermolysis for permanent hair removal. Journal of the American Academy of Dermatology 1985 12 441-449. (doi:10.1016/S0190-9622(85)70062-X)
270. Haedersdal M & Gøtzsche PC. Laser and photoepilation for unwanted hair growth. Cochrane Database of Systematic Reviews 2006 CD004684.
271. Wolf JE Jr, Shander D, Huber F, Jackson J, Lin CS, Mathes BM, Schrode K & Eflornitine HCI Study Group. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. International Journal of Dermatology 2007 46 94-98. (doi:10.1111/j.1365-4632.2006.03079.x)
272. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction 2008 23 462-477. (doi:10.1093/humrep/dem426)
273. Kousta E, White DM & Franks S. Modern use of clomiphene citrate in induction of ovulation. Human Reproduction Update 1997 3 359-365. (doi:10.1093/humupd/3.4.359)
274. Polson DW, Kiddy DS, Mason HD & Franks S. Induction of ovulation with clomiphene citrate in women with polycystic ovary syndrome: the difference between responders and nonresponders. Fertility and Sterility 1989 51 30-34.
275. Imani B, Eijkemans MJ, Faessen GH, Bouchard P, Giudice LC & Fauser BC. Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertility and Sterility 2002 77 83-90. (doi:10.1016/S0015-0282(01)02928-4)
276. Rausch ME, Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, McGovern PG, Cataldo NA et al. Predictors of pregnancy in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2009 94 3458-3466. (doi:10.1210/jc.2009-0545)
277. Misso ML, Wong JL, Teede HJ, Hart R, Rombauts L, Melder AM, Norman RJ & Costello MF. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. Human Reproduction Update 2012 18 301-312. (doi:10.1093/humupd/dms003)
278. White DM, Polson DW, Kiddy D, Sagle P, Watson H, Gilling-Smith C, Hamilton-Fairley D & Franks S. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. Journal of Clinical Endocrinology and Metabolism 1996 81 3821-3824.
279. Gorry A, White DM & Franks S. Infertility in polycystic ovary syndrome. Endocrine 2006 30 27-33. (doi:10.1385/ENDO:30:1:27)
280. Bayram N, van Wely M, Kaaijk EM, Bossuyt PM & van der Veen F. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ 2004 328 192. (doi:10.1136/bmj.328.7433.192)
281. Farquhar C, Lilford RJ, Marjoribanks J & Vandekerckhove P. Laparoscopic 'drilling' by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 2007 CD001122.
282. Lord JM, Flight IH & Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003 327 951-953. (doi:10.1136/bmj.327.7421.951)
283. Tang T, Glanville J, Hayden CJ, White DM, Barth JH & Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Human Reproduction 2006 21 80-89. (doi:10.1093/humrep/dei311)
284. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB & van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomized double blind clinical trial. BMJ 2006 332 1485. (doi:10.1136/bmj. 38867.631551.55)
285. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine 2007 356 551-566. (doi:10.1056/NEJMoa063971)